In a recent series of papers, LeRoith and colleagues utilized a mouse model of genetically induced insulin resistance that develops hyperinsulinemia without obesity to examine how insulin signaling impacts mammary tumor growth in vivo. The gene discussed is INS; the disease is hyperinsulinism.